Equities analysts expect that OncoSec Medical Inc (NASDAQ:ONCS) will post ($0.20) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for OncoSec Medical’s earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.19). The business is expected to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that OncoSec Medical will report full-year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.74) to ($0.60). For the next year, analysts forecast that the company will report earnings of ($0.84) per share. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for OncoSec Medical.
A number of analysts have weighed in on the stock. Piper Jaffray Companies restated an “overweight” rating on shares of OncoSec Medical in a research note on Monday, October 15th. HC Wainwright lowered shares of OncoSec Medical from a “buy” rating to a “neutral” rating in a research note on Wednesday. Finally, Dawson James restated a “buy” rating on shares of OncoSec Medical in a research note on Monday, July 16th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. OncoSec Medical presently has an average rating of “Buy” and an average target price of $4.00.
Several hedge funds have recently made changes to their positions in the company. Nexthera Capital LP grew its stake in shares of OncoSec Medical by 26.6% in the second quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after acquiring an additional 550,000 shares during the period. Millennium Management LLC grew its stake in shares of OncoSec Medical by 19.5% in the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after acquiring an additional 194,739 shares during the period. 683 Capital Management LLC bought a new stake in shares of OncoSec Medical in the second quarter worth approximately $414,000. BlackRock Inc. grew its stake in shares of OncoSec Medical by 1,303.5% in the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after acquiring an additional 221,916 shares during the period. Finally, DRW Securities LLC grew its stake in shares of OncoSec Medical by 157.1% in the second quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 110,000 shares during the period. Hedge funds and other institutional investors own 23.13% of the company’s stock.
NASDAQ:ONCS traded up $0.02 on Friday, reaching $0.86. 2,243,700 shares of the stock traded hands, compared to its average volume of 1,135,846. The firm has a market cap of $51.72 million, a P/E ratio of -0.81 and a beta of 2.28. OncoSec Medical has a 12 month low of $0.68 and a 12 month high of $2.95.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Featured Article: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.